Feb 28, 2017 7:00am EST Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at the Cowen and Company 37th Annual Health Care Conference
Feb 9, 2017 7:00am EST Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at the 2017 BIO CEO & Investor Conference
Jan 24, 2017 7:00am EST Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at NobleCon13
Jan 10, 2017 1:00pm EST Tonix Pharmaceuticals Presented Details of Newly Expanded Product Development Pipeline at 9th Annual Biotech Showcase Conference
Jan 3, 2017 7:00am EST Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at 9th Annual Biotech Showcase Conference
Dec 19, 2016 7:00am EST Tonix Pharmaceuticals’ PTSD Phase 3-Ready Drug Candidate, TNX-102 SL, Granted Breakthrough Therapy Designation by the FDA
Dec 8, 2016 7:00am EST Tonix Pharmaceuticals Presented New Clinical Results from Sub-Group Analysis of Phase 2 AtEase Study in Military-Related Posttraumatic Stress Disorder (PTSD)
Dec 2, 2016 7:21am EST Tonix Pharmaceuticals to Present Clinical Data at the 55th Annual Meeting of the American College of Neuropsychopharmacology (ACNP)
Nov 30, 2016 7:00am EST Tonix Pharmaceuticals to Present at 9th Annual LD Micro Main Event Investor Conference